Tramadol News and Research

RSS
Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Ampio submits pre-IND package on Zertane to FDA

Ampio submits pre-IND package on Zertane to FDA

ASN participates in ABIM Foundation's Choosing Wisely campaign

ASN participates in ABIM Foundation's Choosing Wisely campaign

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio, Australian TGA reach agreement over Zertane submission plan

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

New ACR guidelines recommend use of topical NSAIDs for older patients with knee OA

New NPS information on dextropropoxyphene: recommendations and alternatives

New NPS information on dextropropoxyphene: recommendations and alternatives

Ampio announces two new European patents for Zertane combination therapy

Ampio announces two new European patents for Zertane combination therapy

Medical websites provide harmful information about postherpetic neuralgia treatments

Medical websites provide harmful information about postherpetic neuralgia treatments

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Cipher grants Vertical exclusive U.S. distribution rights to CIP-TRAMADOL ER

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher first quarter net revenue decreases to $0.7 million

Cipher first quarter net revenue decreases to $0.7 million

Labopharm first quarter total revenue increases to $5.3 million

Labopharm first quarter total revenue increases to $5.3 million

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm third quarter total revenue increases to $9.6 million

Labopharm third quarter total revenue increases to $9.6 million